Study of LP-184 in Patients With Advanced Solid Tumors
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
In brief
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity
Key facts
- Study ID
- NCT05933265
- Run by
- Lantern Pharma Inc.
- People needed
- 64
- Starts
- 2023-06-09
- Expected to finish
- 2026-07-28
- Last updated by the study team
- 2026-05-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Highlands Oncology Group — Springdale, Arkansas, United States
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
- Norton Healthcare, Inc. — Louisville, Kentucky, United States
- John Hopkins - The Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- UT Health Science Center San Antonio — San Antonio, Texas, United States
- START Mountain Region — West Valley City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.